Taiwan consensus of pharmacological treatment for bipolar disorder

Journal of the Chinese Medical Association

Volumn 76, Issue 10, 2013, Pages 547-556

  Bai, Ya Mei ^a,b   Chang, Ching Jui ^c,d   Tsai, Shang Ying ^e,f   Chen, Yi Chyan ^g   Hsiao, Mei Chun ^h   Li, Cheng Ta ^a,b   Tu, Peichi ^a,b   Chang, Shang Wen ^b,i   Shen, Winston W ^e,j   Su, Tung Ping ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^h CHANG GUNG UNIVERSITY   (Taiwan)

ⁱ SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^j TAIPEI MEDICAL UNIVERSITY   (Taiwan)

more..

Author keywords

Bipolar disorder; Consensus; Pharmacotherapy; Taiwan

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROMAZINE; CLOTIAPINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LOXAPINE; OLANZAPINE; OXCARBAZEPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; VALPROIC ACID; ZIPRASIDONE; ZOTEPINE;

AGRANULOCYTOSIS; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CONSENSUS; DRUG EFFICACY; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; GENOTYPE; HUMAN; MANIA; METABOLIC SYNDROME X; NATIONAL HEALTH INSURANCE; NERVE STIMULATION; NEUROPHARMACOLOGY; PRACTICE GUIDELINE; RASH; REVIEW; SEDATION; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TAIWAN; TOXIC EPIDERMAL NECROLYSIS; WEIGHT GAIN;

BIPOLAR DISORDER; CONSENSUS; PHARMACOTHERAPY; TAIWAN;

BIPOLAR DISORDER; CONSENSUS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAIWAN;

EID: 84884587312     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2013.06.013     Document Type: Review

References (92)

1. Yatham L.N., Kennedy S.H., Parikh S.V., Schaffer A., Beaulieu S., Alda M., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009, 11:225-255.
2. Bih S.H., Chien I.C., Chou Y.J., Lin C.H., Lee C.H., Chou P. The treated prevalence and incidence of bipolar disorder among national health insurance enrollees in Taiwan, 1996-2003. Soc Psychiatry Psychiatr Epidemiol 2008, 43:860-865.
3. Huang K.L., Su T.P., Chen T.J., Chou Y.H., Bai Y.M. Comorbidity of cardiovascular diseases with mood and anxiety disorder: a population based 4-year study. Psychiatry Clin Neurosci 2009, 63:401-409.
4. Chien I.C., Chou Y.J., Lin C.H., Bih S.H., Chou P. Prevalence of psychiatric disorders among National Health Insurance enrollees in Taiwan. Psychiatr Serv 2004, 55:691-697.
5. Grunze H., Vieta E., Goodwin G.M., Bowden C., Licht R.W., Möller H.J., et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009, 10:85-116.
6. Grunze H., Vieta E., Goodwin G.M., Bowden C., Licht R.W., Möller H.J., et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010, 11:81-109.
7. Goodwin G.M. Evidence-based guidelines for treating bipolar disorder: revised second edition - recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009, 23:346-388.
8. Smith L.A., Cornelius V., Warnock A., Bell A., Young A.H. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007, 9:394-412.
9. Smith L.A., Cornelius V., Warnock A., Tacchi M.J., Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007, 9:551-560.
10. Smith L.A., Cornelius V., Warnock A., Tacchi M.J., Taylor D. Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scand 2007, 115:12-20.
11. Ceron-Litvoc D., Soares B.G., Geddes J., Litvoc J., de Lima M.S. Comparison of carbamazepine and lithium in treatment of bipolar disorder: a systematic review of randomized controlled trials. Hum Psychopharmacol 2009, 24:19-28.
12. Owen R.T. Extended-release carbamazepine for acute bipolar mania: a review. Drugs Today (Barc) 2006, 42:283-289.
13. Weisler R.H., Keck P.E., Swann A.C., Cutler A.J., Ketter T.A., Kalali A.H. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005, 66:323-330.
14. Zhang Y., Wang J., Zhao L.M., Peng W., Shen G.Q., Xue L., et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol 2011, 67:885-887.
15. Hu F.Y., Wu X.T., An D.M., Yan B., Stefan H., Zhou D. Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population. Seizure 2011, 20:160-162.
16. An D.M., Wu X.T., Hu F.Y., Yan B., Stefan H., Zhou D. Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population. Epilepsy Res 2010, 92:226-230.
17. Ferrell P.B., McLeod H.L. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008, 9:1543-1546.
18. Chung W.H., Hung S.I., Hong H.S., Hsih M.S., Yang L.C., Ho H.C., et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004, 428:486.
19. Lin C.H., Lu C.H., Wang F.J., Tsai M.H., Chang W.N., Tsai N.W., et al. Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy. Clin Neuropharmacol 2010, 33:293-296.
20. Dong X., Leppik I.E., White J., Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005, 65:1976-1978.
21. Kakkar A.K., Rehan H.S., Unni K.E., Gupta N.K., Chopra D., Kataria D. Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study. Eur Psychiatry 2009, 24:178-182.
22. Niufan G., Tohen M., Qiuqing A., Fude Y., Pope E., McElroy H., et al. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J Affect Disord 2008, 105:101-108.
23. Perlis R.H., Baker R.W., Zarate C.A., Brown E.B., Schuh L.M., Jamal H.H., et al. Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry 2006, 67:1747-1753.
24. Citrome L. Drug safety evaluation of ziprasidone. Expert Opin Drug Safety 2011, 10:437-448.
25. DelBello M.P., Kowatch R.A., Adler C.M., Stanford K.E., Welge J.A., Barzman D.H., et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006, 45:305-313.
26. Pajonk F.G., Schwertner A.K., Seelig M.A. Rapid dose titration of quetiapine for the treatment of acute schizophrenia and acute mania: a case series. J Psychopharmacol 2006, 20:119-124.
27. Khazaal Y., Tapparel S., Chatton A., Rothen S., Preisig M., Zullino D. Quetiapine dosage in bipolar disorder episodes and mixed states. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:727-730.
28. Gandelman K., Alderman J.A., Glue P., Lombardo I., LaBadie R.R., Versavel M., et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J Clin Psychopharmacol 2009, 70:58-62.
29. Berwaerts J., Lane R., Nuamah I.F., Lim P., Remmerie B., Hough D.W. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord 2011, 129:252-260.
30. Berwaerts J., Xu H., Nuamah I., Lim P., Hough D. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. J Affect Disord 2010, 136:e51-e60.
31. Vieta E., Nuamah I.F., Lim P., Yuen E.C., Palumbo J.M., Hough D.W., et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 2010, 12:230-243.
32. Thomas P., Vieta E. Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial. Neuropsychiatr Dis Treat 2008, 4:675-686.
33. Masi G., Mucci M., Millepiedi S. Clozapine in adolescent inpatients with acute mania. J Child Adolesc Psychopharmacol 2002, 12:93-99.
34. Green A.I., Tohen M., Patel J.K., Banov M., DuRand C., Berman I., et al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000, 157:982-986.
35. Calabrese J.R., Kimmel S.E., Woyshville M.J., Rapport D.J., Faust C.J., Thompson P.A., et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996, 153:759-764.
36. Chan H.Y., Jou S.H., Juang Y.Y., Chang C.J., Chen J.J., Chen C.H., et al. A single-blind, comparative study of zotepine versus haloperidol in combination with a mood stabilizer for patients with moderate-to-severe mania. Psychiatry Clin Neurosci 2010, 64:162-169.
37. Amann B., Sterr A., Mergl R., Dittmann S., Seemüller F., Dobmeier M., et al. Zotepine loading in acute and severely manic patients: a pilot study. Bipolar Disord 2005, 7:471-476.
38. Harada T., Otsuki S. Antimanic effect of zotepine. Clin Ther 1986, 8:406-414.
39. Cipriani A., Rendell J.M., Geddes J.R. Haloperidol alone or in combination for acute mania. Cochrane Database Syst Rev 2006, 3:CD004362.
40. Klein D.F. Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry 1967, 16:118-126.
41. Volpe F.M., Tavares A. Manic patients receiving ECT in a Brazilian sample. J Affect Disord 2004, 79:201-208.
42. Sikdar S., Kulhara P., Avasthi A., Singh H. Combined chlorpromazine and electroconvulsive therapy in mania. Br J Psychiatry 1994, 164:806-810.
43. Mukherjee S., Sackeim H.A., Schnur D.B. Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience. Am J Psychiatry 1994, 151:169-176.
44. Kaptsan A., Yaroslavsky Y., Applebaum J., Belmaker R.H., Grisaru N. Right prefrontal TMS versus sham treatment of mania: a controlled study. Bipolar Disord 2003, 5:36-39.
45. Scherk H., Pajonk F.G., Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007, 64:442-455.
46. Tohen M., Bowden C.L., Smulevich A.B., Bergstrom R., Quinlan T., Osuntokun O., et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008, 192:135-143.
47. Calabrese J.R., Keck P.E., Macfadden W., Minkwitz M., Ketter T.A., Weisler R.H., et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162:1351-1360.
48. Thase M.E., Macfadden W., Weisler R.H., Chang W., Paulsson B., Khan A., et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006, 26:600-609.
49. Suppes T., Hirschfeld R.M., Vieta E., Raines S., Paulsson B. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 2008, 9:198-211.
50. Suppes T., Datto C., Minkwitz M., Nordenhem A., Walker C., Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010, 121:106-115.
51. Weisler R.H., Calabrese J.R., Thase M.E., Arvekvist R., Stening G., Paulsson B., et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008, 69:769-782.
52. Young A.H., McElroy S.L., Bauer M., Philips N., Chang W., Olausson B., et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010, 71:150-162.
53. McElroy S.L., Weisler R.H., Chang W., Olausson B., Paulsson B., Brecher M., et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010, 71:163-174.
54. Calabrese J.R., Bowden C.L., Sachs G.S., Ascher J.A., Monaghan E., Rudd G.D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999, 60:79-88.
55. Calabrese J.R., Huffman R.F., White R.L., Olausson B., Paulsson B., Brecher M., et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008, 10:323-333.
56. Geddes J.R., Calabrese J.R., Goodwin G.M. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009, 194:4-9.
57. Tomson T., Battino D., Bonizzoni E., Craig J., Lindhout D., Sabers A., et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011, 10:609-617.
58. Shallcross R., Bromley R.L., Irwin B., Bonnett L.J., Morrow J., Baker G.A. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 2011, 76:383-389.
59. McIntyre R.S., Mancini D.A., McCann S., Srinivasan J., Kennedy S.H. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord 2003, 5:28-35.
60. Joffe H., Taylor A.E., Hall J.E. Polycystic ovarian syndrome - relationship to epilepsy and antiepileptic drug therapy. J Clin Endocrinol Metab 2001, 86:2946-2949.
61. Genton P., Bauer J., Duncan S., Taylor A.E., Balen A.H., Eberle A., et al. On the association between valproate and polycystic ovary syndrome. Epilepsia 2001, 42:295-304.
62. Zornberg G.L., Pope H.G. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993, 13:397-408.
63. Tohen M., Vieta E., Calabrese J., Ketter T.A., Sachs G., Bowden C., et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003, 60:1079-1088.
64. Brown E.B., McElroy S.L., Keck P.E., Deldar A., Adams D.H., Tohen M., et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006, 67:1025-1033.
65. Zhang Z.J., Kang W.H., Tan Q.R., Li Q., Gao C.G., Zhang F.G., et al. Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. J Psychiatr Res 2007, 41:360-369.
66. Sachs G.S., Nierenberg A.A., Calabrese J.R., Marangell L.B., Wisniewski S.R., Gyulai L., et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007, 356:1711-1722.
67. Goldberg J.F., Perlis R.H., Ghaemi S.N., Calabrese J.R., Bowden C.L., Wisniewski S., et al. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am J Psychiatry 2007, 164:1348-1355.
68. Calabrese J.R., Ketter T.A., Youakim J.M., Tiller J.M., Yang R., Frye M.A. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry 2010, 71:1363-1370.
69. Gupta S., Vincent J.L., Frank B. Pramipexole: augmentation in the treatment of depressive symptoms. CNS Spectrums 2006, 11:172-175.
70. Zarate C.A., Payne J.L., Singh J., Quiroz J.A., Luckenbaugh D.A., Denicoff K.D., et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004, 56:54-60.
71. Sporn J., Ghaemi S.N., Sambur M.R., Rankin M.A., Recht J., Sachs G.S., et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000, 12:137-140.
72. Frye M.A., Grunze H., Suppes T., McElroy S.L., Keck P.E., Walden J., et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007, 164:1242-1249.
73. Nasr S., Wendt B., Steiner K. Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice. J Affect Disord 2006, 95:111-114.
74. Bocchetta A., Bernardi F., Burrai C., Pedditzi M., Del Zompo M. A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives. Acta Psychiatr Scand 1993, 88:434-439.
75. Kessler U., Vaaler A.E., Schoyen H., Oedegaard K.J., Bergsholm P., Andreassen O.A., et al. The study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disorder. BMC Psychiatry 2010, 10:16.
76. Su T.P., Huang C.C., Wei I.H. Add-on rTMS for medication-resistant depression: a randomized, double-blind, sham-controlled trial in Chinese patients. J Clin Psychiatry 2005, 66:930-937.
77. Grunze H., Kasper S., Goodwin G., Bowden C., Moller H.J. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry 2004, 5:120-135.
78. Swann A.C. Long-term treatment in bipolar disorde. J Clin Psychiatry 2005, 66(Suppl1):7-12.
79. Fagiolini A., Casamassima F., Mostacciuolo W., Forgione R., Goracci A., Goldstein B.I. Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder. Expert Opin Pharmacother 2010, 11:1727-1740.
80. Bowden C.L., Vieta E., Ice K.S., Schwartz J.H., Wang P.P., Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010, 71:130-137.
81. Woo Y.S., Bahk W.M., Chung M.Y., Kim D.H., Yoon B.H., Lee J.H., et al. Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial. Hum Psychopharmacol 2011, 26:543-553.
82. Marcus R., Khan A., Rollin L., Morris B., Timko K., Carson W., et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011, 13:133-144.
83. Arvilommi P., Suominen K., Mantere O., Leppamaki S., Valtonen H.M., Isometsa E. Maintenance treatment received by patients with bipolar I and II disorders-a naturalistic prospective study. J Affect Disord 2010, 121:116-126.
84. Ghaemi S.N., Wingo A.P., Filkowski M.A., Baldessarini R.J. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand 2008, 118:347-356.
85. Sachs G.S., Thase M.E. Bipolar disorder therapeutics: maintenance treatment. Biol Psychiatry 2000, 48:573-581.
86. Amsterdam J.D., Shults J. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?. J Affect Disord 2009, 115:234-240.
87. Post R.M., Altshuler L.L., Leverich G.S., Frye M.A., Nolen W.A., Kupka R.W., et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006, 189:124-131.
88. Goodwin G.M., Anderson I., Arango C., Bowden C.L., Henry C., Mitchell P.B., et al. ECNP consensus meeting. Bipolar depression. Nice, March 2007. Eur Neuropsychopharmacol 2008, 18:535-549.
89. Freeman M.P., Smith K.W., Freeman S.A., McElroy S.L., Kmetz G.E., Wright R., et al. The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry 2002, 63:284-287.
90. Viguera A.C., Whitfield T., Baldessarini R.J., Craig J., Lindhout D., Sabers A., et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007, 164:1817-1824.
91. Newport D.J., Stowe Z.N., Viguera A.C., Calamaras M.R., Juric S., Knight B., et al. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord 2008, 10:432-436.
92. Yatham L.N., Kennedy S.H., O'Donovan C., Schaffer A., Beaulieu S., Alda M., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005, 7(Suppl3):5-69.